PRMT1

PfPRMT1 (PF3D7_1426200) is a type I protein arginine N-methyltransferase of Plasmodium falciparum that catalyzes formation of monomethylarginine and asymmetric dimethylarginine on substrate arginines, with kinetics comparable to the mammalian enzyme but markedly higher substrate turnover (PMID:19344311). It methylates histones H4 and H2A—modifying histone H4 exclusively at Arg3, a transcription-activating mark that varies dynamically across parasite developmental stages—as well as RNA-metabolism proteins including fibrillarin, poly(A)-binding protein II, ribosomal protein S2, and a putative splicing factor, consistent with a dual role in chromatin-mediated gene regulation and RNA metabolism (PMID:19344311). Consistent with substrates in both compartments, PfPRMT1 localizes predominantly to the cytoplasm with a nuclear fraction (PMID:19344311), and its activity depends on a distinctive N-terminal extension roughly 50 residues longer than the mammalian ortholog (PMID:19344311). Small-molecule PRMT inhibitors block recombinant PfPRMT1 with sub-micromolar potency and impair parasite growth, marking the enzyme as an antiplasmodial target (PMID:19344311).

1. 2009 High

   Establishing whether the Plasmodium enzyme was a bona fide type I PRMT was the first question, and in vitro reconstitution showed it generates both monomethyl- and asymmetric dimethylarginine, defining its catalytic type.

   Evidence In vitro methyltransferase assay with recombinant PfPRMT1 and MS identification of methylation products

   PMID:19344311

   Open questions at the time

   • Does not identify which substrates are methylated in vivo
   • No structural basis for type I product specificity
2. 2009 High

   To connect the enzyme to biological pathways, its substrate repertoire was mapped, revealing histones (H4 methylated specifically at Arg3) and multiple RNA-metabolism proteins, placing PfPRMT1 at the interface of chromatin regulation and RNA processing.

   Evidence In vitro methyltransferase assays with recombinant enzyme, synthetic peptides, and defined protein substrates; MS site mapping

   PMID:19344311

   Open questions at the time

   • In vitro substrate methylation does not prove these are physiological targets in the parasite
   • Functional consequence of each substrate methylation not established
3. 2009 Medium

   Whether the parasite-specific N-terminal extension mattered was tested by truncation, showing it is required for catalysis and marking a divergent feature of the parasite enzyme.

   Evidence Domain deletion/truncation of recombinant PfPRMT1 with in vitro methyltransferase assay

   PMID:19344311

   Open questions at the time

   • Mechanism by which the extension supports activity unknown
   • Single lab, single study
4. 2009 Medium

   To place the enzyme in cellular space relative to its dual substrate classes, localization was determined, showing predominantly cytoplasmic distribution with a nuclear fraction consistent with both histone and RNA-protein substrates.

   Evidence Live GFP imaging and subcellular fractionation/western blot of untagged protein

   PMID:19344311

   Open questions at the time

   • Does not resolve stage-dependent shifts in localization
   • Nuclear vs cytoplasmic substrate engagement not directly demonstrated
5. 2009 Medium

   Whether the H4R3 mark is used dynamically in vivo was addressed by profiling H4R3me2a across development, linking the enzyme's activity to developmentally regulated gene expression.

   Evidence Western blotting with dimethyl-H4-Arg3-specific antibody across parasite stages

   PMID:19344311

   Open questions at the time

   • Antibody signal does not directly attribute the mark to PfPRMT1
   • No genetic knockout to confirm causality
6. 2009 Medium

   To assess druggability, PRMT inhibitors were tested, showing sub-micromolar in vitro inhibition of PfPRMT1 that mostly correlated with parasite growth suppression, nominating the enzyme as an antimalarial target.

   Evidence In vitro PRMT inhibition assay with recombinant enzyme plus parasite growth inhibition assay

   PMID:19344311

   Open questions at the time

   • Growth inhibition not proven to act through PfPRMT1 in cells
   • No target engagement assay
7. 2026 Low

   Extending the druggability question, a chemical repositioning effort nominated PfPRMT1 as the likely cellular target of the multistage-active inhibitor TC-E 5003, supported by a structure-activity relationship.

   Evidence Chemical repositioning screen, SAR analysis of TC-E 5003 analogs, multistage growth inhibition assays

   PMID:41914674

   Open questions at the time

   • Target assignment is proposed, not validated by genetic or biochemical target engagement
   • Single lab, indirect pharmacological evidence

• The in vivo consequences of PfPRMT1 activity remain open: no genetic loss-of-function study establishes which substrates are physiologically methylated or whether PfPRMT1 is essential for parasite viability or stage progression.
• No knockout/knockdown phenotype reported
• Physiological substrates not confirmed in vivo
• No structural model of the parasite enzyme